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Abstract
Senescence, the state of permanent cell cycle arrest, has been associatedwith endothelial cell dysfunction and atherosclerosis.
The cyclin dependent kinase inhibitors p21
CIP1/WAF1 and p16
INK4a govern the G1/S cell cycle checkpoint and are essential for
determining whether a cell enters into an arrested state. The homeodomain transcription factor MEOX2 is an important
regulator of vascular cell proliferation and is a direct transcriptional activator of both p21
CIP1/WAF1 and p16
INK4a. MEOX1 and
MEOX2 have been shown to be partially functionally redundant during development, suggesting that they regulate similar
target genes in vivo. We compared the ability of MEOX1 and MEOX2 to activate p21
CIP1/WAF1 and p16
INK4a expression and
induce endothelial cell cycle arrest. Our results demonstrate for the first time that MEOX1 regulates the MEOX2 target genes
p21
CIP1/WAF1 and p16
INK4a. In addition, increased expression of either of the MEOX homeodomain transcription factors leads to
cell cycle arrest and endothelial cell senescence. Furthermore, we show that the mechanism of transcriptional activation of
thesecyclin dependent kinaseinhibitor genesby MEOX1 andMEOX2 is distinct. MEOX1 andMEOX2 activate p16
INK4a in a DNA
binding dependent manner, whereas they induce p21
CIP1/WAF1 in a DNA binding independent manner.
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Introduction
The G1/S cell cycle checkpoint is critical for determining
whether a cell will enter into S phase and replicate its genome, or
enter into an arrested state and delay cellular proliferation [1].
This state of arrest can be either temporary (quiescence) or it can
be permanent (senescence) [1]. Cells of the adult vasculature
remain in the quiescent state until a need for new blood vessels is
encountered, such as in wound healing [2], menstruation [3] and
exercise [4]. Aged blood vessels, however, have impaired
angiogenic capabilities [5].
Senescence is associated with aging and is also thought to
contribute to atherosclerotic vascular disease [6,7]. It has been
shown in humans that blood vessels with atherosclerotic plaques
contain a higher proportion of senescent vascular smooth muscle
and endothelial cells, as compared to non-atherosclerotic vessels
[8–10]. Senescent endothelial cells have reduced nitric oxide
synthase expression [11–13] and altered metabolism, which results
in endothelial dysfunction and contributes to the progression of
vascular diseases, such as atherosclerosis [6,7].
The cyclin dependent kinase inhibitors (CKIs) p21
CIP1/WAF1
and p16
INK4a block cellular proliferation and govern the G1/S cell
cycle checkpoint [14]. These CKIs bind to cyclin dependent
kinases (CDK2 and/or CDK4), impeding their association with
cyclin proteins (Cyclin E or D, respectively) and thereby prevent
activation of the CDKs. In the absence of activated CDKs, the
subsequent phosphorylation of the retinoblastoma protein, a
requirement for cell cycle progression from G1 to S phase, does
not occur [14]. The CKIs p21
CIP1/WAF1 and p16
INK4a are
encoded by the CDKN1A and CDKN2A genes, respectively and are
currently the only confirmed transcriptional targets of Mesen-
chyme homeobox 2 (MEOX2) [15,16].
Together, MEOX1 and MEOX2 comprise a family of diverged
homeodomain transcription factor proteins. Both MEOX1 and
MEOX2 are expressed in all cells of the adult cardiovasculature,
including cardiomyocytes [17–19], cardiac fibroblasts [17],
vascular smooth muscle and endothelial cells [18,20–22]. The
role of MEOX2 in the vasculature has been extensively studied,
however very little is known about the role of MEOX1 in this
system. MEOX1 has been shown to be expressed in blood, but not
lymphatic, endothelial cells [23] and ectopic MEOX1 expression
induces the cardiomyogenic differentiation of P19 pluripotent
embryonic carcinoma cells [24].
MEOX2 has been shown to prevent vascular cell proliferation by
mediating the transcriptional up-regulation of the p21
CIP1/WAF1
gene and ectopic expression of MEOX2 prevents blood vessel
stenosis [25,26]. MEOX2 expression is diminished in vascular
smooth muscle cells after in vitro mitogen stimulation [27] and in
mechanically injured endothelial cells in vivo [28], thereby
permitting vascular cell proliferation. Likewise blood vessels from
individuals affected by hepatic portal hypertension have lower levels
of MEOX2 expression when compared to non-affected individuals
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blood pressure.
MEOX1 and MEOX2 are necessary for proper bone and
skeletal muscle formation in the developing mouse embryo [30].
Knockout of both MEOX1 and MEOX2 in mice produces a
phenotype that is more severe than the predicted additive
phenotypes of the single MEOX gene knockout mice [30]. This
finding suggests that MEOX1 and MEOX2 have overlapping
functions during embryonic development. Therefore, it is likely
that MEOX1 and MEOX2 share transcriptional target genes.
MEOX1 was shown to function as a direct transcriptional
activator of the NKX3-2/BAPX1 gene by binding to the
NKX3-2 promoter and increasing its expression [31]. Similarly,
MEOX2 was able to bind to the same AT rich consensus site
within the NKX3-2 promoter [31]. We therefore hypothesized
that like MEOX2, MEOX1 would activate the transcription of
p21
CIP1/WAF1 and p16
INK4a in endothelial cells.
In the present study, we investigated the role of MEOX1 and
MEOX2 in controlling endothelial proliferation and senescence, as
well as the mechanisms of transcriptional activation of p21
CIP1/WAF1
and p16
INK4a by the MEOX transcription factors. We demonstrate
for the first time that MEOX1 activates both p21
CIP1/WAF1 and
p16
INK4a expression in endothelial cells and that both MEOX1 and
MEOX2 can effectively induce endothelial cell senescence. In
addition, we show that MEOX1 and MEOX2 activation of
p16
INK4a gene is dependent upon DNA binding whereas their
activation of p21
CIP1/WAF1 gene transcription is via a DNA binding
independent mechanism.
Materials and Methods
MEOX1 and MEOX2 fusion protein expression constructs
Full-length mouse MEOX1 and human MEOX2 were
amplified by PCR from cDNA clones (IMAGE ID 464899 and
3917118, Invitrogen) and cloned into the pCMV-Tag2B or
pcDNA3.1 vectors to create either N-terminal or C-terminal
FLAG tagged fusion proteins, respectively. The DNA binding
deficient constructs MEOX1
Q220E and MEOX2
Q235E were
created by PCR mutagenesis of the MEOX1 and MEOX2
constructs, which changed CAA (Q) to GAA (E) at amino acid
position 220 and 235, respectively. The homeodomain deleted
construct MEOX2
K195_K245del was created by splice overlap
extension PCR [32] to create a MEOX2 construct lacking amino
acids 195-245. All expression constructs were sequence verified.
Additional details regarding the cloning of these constructs and
primer sequences are listed in Table S1.
Adenoviral constructs
Ad-EGFP was a gift from Dr. G. Pierce (University of Manitoba)
and Ad-p53-EGFP was a gift from Dr. N. Mesaeli (Weill Cornell
Medical College in Qatar). Adenovirus encoding N-terminal FLAG
tagged MEOX1 and MEOX2 adenoviral constructs were created
by excising MEOX1 and MEOX2 from the pCMV-Tag2B vector
by NotI/XhoI digestion, followed by ligation intothe pShuttle vector.
Production and amplification of the adenoviral stocks was achieved
using the AdEasy vector system (Qbiogene). Adenoviral titres were
determined using the RapidTiter kit (Clontech).
p21
CIP1/WAF1 and p16
INK4a promoter luciferase constructs
and expression vectors
The WWP-LUC vector, a gift from Dr. B. Vogelstein (Johns
Hopkins University) [33], was digested with SstI/HindIII and the
2272 bp human p21
CIP1/WAF1 promoter was cloned into the
pGL3-basic vector (Promega). The 849 bp, 505 bp, 426 bp and
232 bp p21
CIP1/WAF1 promoters were created using primers listed
in Table S2. The 103 bp p21 promoters (p21P 93-S WT, MT1,
MT2, MT3 and MT4 [34]) were a gift from Dr. B. Sawaya
(Temple University) [35]. The pGL3 vector containing the 564 bp
p16
INK4A promoter (pGL3-INK4a) was a gift from Dr. S. Chanda
(Burnham Institute for Medical Research) [16]. The SP1
expression plasmid (pCMV4-Sp1/flu) was a gift from Dr. J.
Horowitz (North Carolina State University) [36]. The pcDNA3-
lacZ vector was a gift from Dr. N. Mesaeli (Weill Cornell Medical
College in Qatar).
Luciferase assays
HEK293 cells (ATCC) were cultured in HyQ DMEM/High
Glucose (HyClone) containing 5% Fetal Bovine Serum (FBS)
(HyClone) and 1% Penicillin/Streptomycin (Gibco). Human
umbilical vein endothelial cells (HUVECs) (Clonetics) were cultured
in EGM-2 (Clonetics). Media was changed to Opti-MEM I (Gibco)
containing 10% Calf Serum (Gibco) 48 hours after plating 1.5610
5
cells/well. Cells were transfected using Lipofectamine 2000 or
Lipofectamine LTX Reagent (Invitrogen). Additional details can be
found in Methods S1. In all experiments, media was changed back
to growth medium 4 hours post-transfection. Mithramycin A
(200 ng/mL final concentration [37,38]), or the same volume of
methanol (vehicle), was diluted in growth medium and added to the
cells 4 hours post-transfection.
Luciferase assays were performed 24 hours after transfection or
mithramycin A treatment using a Lumat LB 9507 luminometer
and luciferase buffer containing 20 mM Tricine, 1.07 mM
MgCO3, 2.67 mM MgSO4, 0.1 mM EDTA, 33.3 mM DTT,
270 mM coenzyme A, 470 mM luciferin, and 530 mM ATP. b-
galactosidase assays were performed using a solution containing
0.801 mg/mL ONPG and a MRX-TC revelation spectrophotom-
eter (Dynex Technologies) set to 415 nm. To control for
transfection efficiency, luciferase assay values were normalized to
the b-galactosidase assay values for each sample. Empty expression
vectors were used to control for basal promoter activity. Fold
activation was calculated by dividing the relative luciferase unit
value of each sample by the value obtained for the empty vector
control.
Immunofluorescence
HUVECs (1610
5 cells/plate) were transduced at a multiplicity
of infection (MOI) of 250 with adenovirus and then plated onto
collagen I (BD Biosciences) coated glass coverslips. Forty-eight
hours after transduction, cells were fixed in 4% paraformaldehyde
(EMD Chemicals) and then blocked with 5% goat serum (Sigma)
in PBS containing 0.3% Triton-X 100 (PBS-T). Coverslips were
incubated with primary mouse anti-FLAG antibody [M2] (Sigma)
followed by Alexa Fluor 488 conjugated goat anti-mouse IgG
secondary antibody (Invitrogen). Subsequently, coverslips were
incubated with propidium iodide (Invitrogen). The coverslips were
then mounted onto slides using FluorSave Reagent (CalBiochem).
Images were acquired with an Olympus IX70 confocal laser
microscope using FluoView 2.0 software. Additional details can be
found in Methods S1.
Western blotting and quantification
HEK293 cells were cultured as described above. Forty-eight
hours after plating 2610
5 cells/6 cm tissue culture plate, the
media was changed to Opti-MEM I (Gibco) containing 10% Calf
Serum (Gibco). Each plate of cells was then transfected with 4mg
MEOX expression vector DNA using 10 mL Lipofectamine 2000
Reagent (Invitrogen). Media was changed back to growth medium
after 4 hours and cells were harvested 48 hours post-transfection.
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5 trypsinized HUVECs were transduced at 250 MOI with
adenovirus and then plated onto 6 cm tissue culture plates. Cells
were harvested 48–72 hours post-transduction.
For whole cell lysates, cells were harvested using RIPA buffer
(50mM Tris pH 7.4, 150mM NaCl, 1mM EDTA, 1mM EGTA,
0.5% Na-deoxycholate, 1% Triton-X 100 and 0.1% SDS)
containing complete mini protease inhibitor cocktail (Roche).
Whole cell lysates were centrifuged for 15 seconds to pellet cell
debris. To assure equal loading between samples, protein assays
were performed prior to sample preparation using the DC Protein
Assay Kit (Bio-Rad) and an Ultrospec 2000 (Pharmacia Biotech)
or MRX-TC revelation spectrophotometer (Dynex Technologies)
set to 540 nm. Nuclear and cytosolic proteins were isolated using
the NE-PER nuclear and cytoplasmic extraction kit (Pierce). All
samples were prepared with 36 loading buffer (166.4 mM Tris
pH 7.4, 33.3% glycerol, 6.6% SDS, 0.3% bromophenol blue and
100 mM DTT) and then boiled for 5 minutes to denature the
proteins prior to loading.
Proteins were separated by SDS-PAGE and then transferred to
nitrocellulose membranes (Bio-Rad). Primary antibodies used for
western blotting were: mouse anti-FLAG antibody [M2] (Sigma),
mouse anti-a-tubulin antibody [DM1A] (Abcam), mouse anti-
p21
CIP1/WAF1 antibody [CP74] (Sigma), rabbit anti-actin antibody
(Sigma) and mouse anti-p16
INK4a antibody [DCS-50] (Santa
Cruz). A full description of blotting conditions can be found in
Methods S1.
Quantitative real-time PCR
Real-time PCR experiments were performed using RNA from
HUVECs (2.5610
5 cells/plate) transduced at 250 MOI with
adenovirus for 48–72 hours. RNA was isolated using the RNeasy
Plus kit (Qiagen) following the manufacturer’s instructions. One-
step real-time PCR was performed using an iQ5 thermocycler
(BioRad) and the iScript One-Step PCR kit with SybrGreen
(BioRad) or the BR 1-Step SYBR Green qRT-PCR Kit (Quanta).
Relative gene quantification (2
-DDCT method) was performed
where the mRNA expression of p21
CIP1/WAF1 and p16
INK4a was
compared to the mRNA expression of the b-actin control. PCR
products were resolved on 2% agarose gels and cloned using the
TOPO TA cloning kit (Invitrogen). The resulting constructs were
verified by sequencing. Primer sequences are listed in Table S3.
Electrophoretic mobility shift assays (EMSA)
Details about recombinant protein production can be found in
Methods S1. Two hundred nanograms of recombinant GST-
fusion protein was used per EMSA binding reaction. Alternatively,
HUVECs were transduced at a MOI of 50 with adenovirus then
seeded onto tissue culture plates. Nuclear proteins were isolated
using the NE-PER nuclear and cytoplasmic extraction kit (Pierce)
72 hours post-transduction and 5 mL nuclear extract was used per
binding reaction.
EMSAs were carried out using the LightShift Chemiluminescent
EMSA Kit (Pierce). The sequence of the EMSA probes containing
either the distal or the proximal homeodomain binding sites from
the p16
INK4a promoter are listed in Table S4. Binding reactions
(20 mL) were incubated for 30 minutes at room temperature in a
buffer containing 10 mM Tris pH 7.5, 50 mM KCl, 1 mM DTT,
50 ng/ml Poly(dINdC), 5% glycerol, 0.05% NP-40, 3.5mM MgCl2,
0.5 mM EDTA, 0.25 mg/ml BSA and 30 – 90 fmol biotin end-
labelled probe. For cold competition reactions, 8 – 18 pmol
unlabelled probe was added (200 molar excess) and then incubated
for 15 minutes at room temperature prior to the addition of the
biotin labelled probe. Super-shift reactions containing 1 – 1.5 mg
normalmouseIgG (Millipore)oranti-FLAG[M2] antibody (Sigma)
were incubated overnight at 4uC, prior to the addition of biotin
labelled probe. Luminescence was detected using CL-Xposure blue
X-ray film (Thermo Scientific).
Senescence associated b-gal assays
HUVECs (1610
5 cells/well) were transduced with adenovirus
at 250 MOI and then plated onto collagen I (BD Biosciences)
coated glass coverslips. Forty-eight hours post-transduction, cells
were washed twice with PBS and then fixed for 5 minutes at room
temperature with 2% paraformaldehyde (EMD Chemicals) diluted
in PBS. Coverslips were washed twice with PBS and then freshly
prepared SA-b-gal staining solution (40 mM citric acid/sodium
phosphate, pH 6.0, 150 mM NaCl, 2 mM MgCl2,5 m M
potassium ferricyanide, 5 mM potassium ferrocyanide, 1 mg/mL
X-gal) was added and incubated overnight at 37uC [39]. The
following day, coverslips were rinsed three times with double
distilled water. Nuclei were stained with Mayer’s hematoxylin
solution (Sigma) at room temperature for 2 minutes and then
rinsed three times with double distilled water. Coverslips were
mounted onto glass slides using FluorSave Reagent (CalBiochem).
Phase contrast images of 16 random fields (206) per coverslip were
acquired using a Zeiss Axioskop 2 mot plus microscope equipped
with an AxioCam digital camera and AxioVision 4.6 software
(Zeiss). The number of SA-b-gal positive cells was counted by an
observer that was blinded to the identity of the slides and then
expressed as a percentage of the total number of cells counted.
Cell cycle analysis
HUVECs (3610
5 cells/plate) were transduced with adenovirus
at 100 MOI and then plated. Forty-eight hours post-transduction
cells were treated with 59-bromo-29-deoxyuridine (BrdU) (Fisher)
at a final concentration of 10 mM for 1 hour at 37uC + 5% CO2.
Cells were washed three times with PBS, trypsinized and then
pelleted by centrifugation. The cell pellets were resuspended in
0.5 mL PBS, following which 2 mL cold 70% ethanol was added
and the cells were fixed overnight at 4uC. Cells were pelleted by
centrifugation and then resuspended in 1 mL freshly prepared 2N
HCl and incubated at room temperature for 25 minutes.
Subsequently, 2 mL PBS containing 3% FBS (PBS/FBS) was
added to the cells, which were then pelleted by centrifugation. The
cell pellet was resuspended in 1 mL 0.1 M sodium borate pH 8.5
and incubated at room temperature for 2 minutes. PBS/FBS
(2 mL) was added to the cells, which were then pelleted by
centrifugation. This step was repeated, following which cells were
resuspended in 0.1 mL PBS/FBS containing 5 mL Alexa Fluor 488
conjugated mouse anti-BrdU [MoBU-1] antibody and then
incubated for 2 hours at room temperature. Subsequently, 2 mL
PBS/FBS was added to the cells, which were then pelleted by
centrifugation. Lastly, the cell pellet was then resuspended in
0.5 mL PBS/FBS containing 10 mL 0.2 mg/mL 7-aminoactino-
mycin D (7-AAD) (Invitrogen) and incubated for 15 minutes at
room temperature. All centrifugation steps were carried out at 350
6 g for 5 minutes at room temperature. 1610
4 gated cells per
sample were counted using a BD FACSCalibur flow cytometer.
The results were analyzed using FlowJo software (Tree Star, Inc.).
Apoptosis assays
HUVECs (1610
5 cells/well) were transduced with adenovirus
at 250 MOI and then plated onto collagen I (BD Biosciences)
coated glass coverslips. Prior to fixation, one plate of HUVECs
was treated with staurosporine (Fisher) at a final concentration of
2.5 mM for 4 hours at 37uC + 5% CO2. 48 hours post-
transduction, cells were washed once with PBS and then fixed
for 30 minutes at room temperature with 4% paraformaldehyde
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PBS-T and then terminal deoxyuridine nick end labelled
(TUNEL) using the In Situ Cell Death Detection Kit with TMR
red (Roche). Briefly, the washed coverslips were incubated with the
TUNEL reaction mixture for 60 minutes at room temperature,
rinsed three times with PBS and then mounted onto glass slides
using SlowFade Gold antifade reagent with DAPI (Invitrogen).
Fluorescence images of 16 random fields (206) per coverslip were
acquired using a Zeiss Axioskop 2 mot plus microscope. The
number of TUNEL positive nuclei was counted by an observer
that was blinded to the identity of the slides and then expressed as
a percentage of the total number of nuclei counted.
Statistical analysis
Two-Sample t-tests were used to evaluate the changes between
MEOX proteins and the empty vector as well as to compare the
effect of MEOX1 to that of MEOX2 for luciferase assay data.
Pair-Sample T-tests were used to evaluate the changes between
MEOX proteins and the EGFP control as well as to compare the
effect of MEOX1 to that of MEOX2 for all other experiments.
Changes were considered significant if the p-value was less than
0.05. Statistical analysis was performed using Origin 8.5 software.
Results
Expression and subcellular localization of the MEOX
proteins
We analyzed the degree of conservation between the various
functional domains of MEOX1 and MEOX2 (Figure 1A). While
the MEOX homeodomains (HD) are nearly identical (95%), there
is only a low degree of homology between MEOX1 and MEOX2
outside of this domain. The N-terminus (N) and middle domain
(MID) are the next most conserved regions of these proteins, with
only 35% and 38% amino acid identity, respectively. Unlike
MEOX2, MEOX1 does not contain a histidine/glutamine (HQ)
rich domain, which is a putative transactivation domain [15].
MEOX1 and MEOX2 expression constructs (Figure 1A) were
generated with a FLAG epitope at either the N-terminus or the C-
terminus of the protein. In addition to wild-type MEOX1 and
MEOX2, we created constructs in which the homeodomains were
mutated in order to study the DNA binding requirement of MEOX
protein function. The MEOX1
Q220E and the MEOX2
Q235E
constructs contain the entire MEOX homeodomain, but include
a glutamine to glutamate substitution at position 50 of the
homeodomain (Figure 1A). This mutation has previously been
shown to result in DNA binding defective homeodomain proteins
[40,41]. As well, a deletion version of MEOX2 was generated,
MEOX2
K195_K245del, which lacks nearly the entire homeodomain
(Figure 1A).
The level of expression and localization of the various FLAG
tagged MEOX proteins were verified by western blot and
fluorescent immunocytochemistry. Comparable levels of protein
expression were observed by western blot of MEOX transfected
HEK293 cell lysates (Figure 1B; Figure S1, panel A) and Ad-
MEOX transduced HUVEC lysates (Figure S1, panel B). MEOX1
and MEOX2 were localized predominantly to the nucleus,
although MEOX1 was also consistently detected in the cytoplasm
(Figure 1C, 1D). MEOX1
Q220E and MEOX2
Q235E were both
localized to the nucleus, however an increased amount of cytosolic
protein was detected for both mutants as compared to the wild-type
MEOX proteins (Figure 1C). In contrast, MEOX2
K195_K245del
differed dramatically in localization from that of either the wild-type
MEOX2 or the MEOX2
Q235E proteins, as it was detected pre-
dominantly in the cytoplasm and also as punctate nuclear
aggregates (Figure 1C, 1D). Further use of this construct was
therefore halted, given this confounding factor of altered subcellular
localization.
The FLAG epitope did not affect the expression of the MEOX
proteins, as similar levels of expression and subcellular localization
were obtained for N- and C-terminally tagged constructs (data not
shown). Likewise, luciferase assays performed with N-, C- and
non-tagged versions of MEOX2 confirmed that the FLAG epitope
does not affect the ability of MEOX2 to induce transcription
(Figure S2).
MEOX1 activates p21
CIP1/WAF1 expression in endothelial
cells
To assess the ability of MEOX1 and MEOX2 to induce the
expression of endogenous p21
CIP1/WAF1 in endothelial cells, we
transduced HUVECs using adenoviral vectors, following which we
performed quantitative real-time PCR and western blot analysis to
measure the changes in p21
CIP1/WAF1 expression at the mRNA
and protein level, respectively. Ectopic expression of p53 was used
as a positive control for the induction of p21, since p53 is a well
characterized transcriptional activator of the p21
CIP1/WAF1 gene
[33,42]. Compared to the EGFP control, we observed a three-fold
increase in p21
CIP1/WAF1 mRNA levels and more than a two-fold
increase in p21
CIP1/WAF1 protein levels 48 hours after adenoviral
delivery of p53 (Figure 2A, 2C). Likewise, expression of MEOX1
or MEOX2 resulted in significantly increased p21
CIP1/WAF1
mRNA expression. Interestingly, although MEOX1 was as
effective as MEOX2 at inducing p21
CIP1/WAF1 mRNA expression
(Figure 2A), this potency did not correlate with a similar induction
of p21
CIP1/WAF1 protein (Figure 2B, 2C). MEOX2 increased
p21
CIP1/WAF1 protein expression comparable to p53, however,
MEOX1 was a significantly less potent inducer of p21
CIP1/WAF1
protein as compared to MEOX2 (Figure 2C). Next, we tested the
ability of MEOX1 to activate transcription of a p21
CIP1/WAF1
reporter gene. Comparable to MEOX2, MEOX1 activated the
expression of a luciferase reporter from the 2272 bp p21
CIP1/WAF1
promoter in HEK293 cells (Figure 2D). This activation was also
seen in HUVECs (Figure 2D).
MEOX1 activates p16
INK4a expression in endothelial cells
p16
INK4a has also been shown to be a transcriptional target of
MEOX2. Therefore, we wanted to compare the activation of
p21
CIP1/WAF1 and p16
INK4a by the two MEOX proteins in
endothelial cells. First, we assessed the induction of endogenous
p16
INK4a expression in HUVECs and found that MEOX1 is a
more potent activator (three fold) of p16
INK4a gene expression as
compared to MEOX2 (Figure 3A). Similar to what was observed
for the mRNA expression, both MEOX1 and MEOX2 increased
p16
INK4a protein levels, however the induction of p16
INK4a protein
by MEOX1 was much greater (Figure 3B, 3C). Although we
observed a small but significant increase in p16
INK4a mRNA
expression with MEOX2
Q235E, this activation did not result in
increased protein expression, as assessed by western blot analysis
(Figure 3A, 3B, 3C). Next, we used a 564 bp p16
INK4a promoter
previously shown to be responsive to MEOX2 [16] in U2OS
osteosarcoma cells. This p16
INK4a promoter construct contains
two putative homeodomain binding sites (Figure 3D). In luciferase
reporter gene assays, both MEOX1 and MEOX2 activated
transcription from the 564 bp p16
INK4a promoter in HUVECs,
when compared to the empty vector control; however, MEOX1
was a significantly more potent inducer of the p16
INK4a reporter
gene than MEOX2 (Figure 3E). The DNA binding mutants,
MEOX1
Q220E and MEOX2
Q235E, did not activate transcription
from this p16
INK4a promoter in HUVECs (Figure 3E). Taken
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MEOX2 in the different functional protein domains. B) Representative western blot displaying the relative level of MEOX1 (MX1), MEOX2 (MX2), DNA
binding deficient MEOX1
Q220E (Q220E), DNA binding deficient MEOX2
Q235E (Q235E) and homeodomain deleted MEOX2
K195_K245del (K195_K245del)
protein expression in HEK293 cells 48 hours after transfection. The N-terminally tagged MEOX proteins were detected using an anti-FLAG antibody
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bind DNA, via the homeodomain, is required to activate p16
INK4a
expression.
MEOX1 and MEOX2 bind only the proximal
homeodomain binding site within the p16
INK4a promoter
Subsequently, we wanted to determine which of the two
putative homeodomain binding sites in the 564 bp p16
INK4a
promoter were bound by MEOX1 and MEOX2. Since
MEOX1
Q220E and MEOX2
Q235E did not activate p16
INK4a
expression, we hypothesized that MEOX activation of p16
INK4a
requires DNA binding and therefore the MEOX proteins would
bind to one, or both, of the homeodomain binding sites within this
promoter. To address this question, we designed EMSA probes
which contained either the distal or proximal homeodomain
binding sites.
With both recombinant proteins (Figure 4A) and HUVEC
nuclear extracts (Figure 4B), we observed that MEOX1 and
MEOX2 bound to a DNA probe which contains the proximal, but
not the distal homeodomain binding site. As predicted,
MEOX2
Q235E did not bind to either of the p16
INK4a probes
(Figure 4A, 4B). When the Distal probe was incubated with
recombinant GST-tagged MEOX proteins, no protein-DNA
complexes were formed (Figure 4A, left). Incubation of the Distal
probe with HUVEC nuclear extracts produced three different
sized complexes; however, none of these complexes were specific
to MEOX protein expression (Figure 4B, left). In contrast,
incubation of the Proximal probe with nuclear lysates derived
from either MEOX1 or MEOX2 transduced cells produced
specific protein-DNA complex formation (Figure 4A, right; 4B,
right). Intriguingly, two different sized complexes were observed in
the presence of MEOX1, but only one complex was seen in the
presence of MEOX2. To ensure that the shifts seen when the
nuclear extracts from HUVECs expressing FLAG tagged
MEOX1 or MEOX2 were due to MEOX protein/Proximal
probe interaction, we added an anti-FLAG antibody to the
reaction mixture. Binding of the anti-FLAG antibody to the
specific MEOX protein/Proximal probe complexes caused these
complexes to super-shift, resulting in the formation of a larger
complex (Figure 4B, right, arrowhead; Figure S3, panel A) and a
corresponding reduction in the intensity of the smaller complex
(Figure 4B, right, arrows; Figure S3, panel A).
To confirm that MEOX protein/Proximal probe interaction
was dependent upon the homeodomain binding site within the
probe, the ATTA motif (WT) was mutated to AGGA (MT).
Competition reactions show that the WT probe, but not the MT
probe, competed for binding to MEOX1 and MEOX2 (Figure S3,
panel B).
Increased MEOX1 or MEOX2 expression leads to
increased endothelial cell senescence.
As p21
CIP1/WAF1 and p16
INK4a are involved in the regulation of
the cell-cycle, we tested whether MEOX1 and MEOX2 could
induce changes in cellular proliferation. 5-bromo-2-deoxyuridine
(BrdU) incorporation into the DNA of cycling HUVECs was used
to detect changes in the percentage of cells in S phase of the cell
cycle. As expected, expression of p53 in HUVECs (positive control)
resulted in a significant decrease in the percentage of S phase cells as
compared to the EGFP control (Figure 5A, 5B). Likewise, we
observed a decrease in the proportion of S phase cells when
MEOX1 or MEOX2 were expressed in HUVECs (Figure 5A, 5B).
MEOX1 had the greatest effect on cellular proliferation and
MEOX2
Q235E decreased the proportionof S phase cells to the same
extent as wild-type MEOX2 (Figure 5A, 5B).
Unlike quiescence (reversible cell cycle arrest), senescence is a
state of permanent cell cycle arrest and is associated with an
increase in both p21
CIP1/WAF1 and p16
INK4a protein expression.
Thus, we ascertained whether the increased p21
CIP1/WAF1 and
p16
INK4a expression induced by MEOX1 and MEOX2 results in
increased endothelial cell senescence. When MEOX1 or MEOX2
was expressed in HUVECs, we observed a significant increase in
the number of senescent cells (approximately 2-fold) (Figure 5D),
as assessed by senescence-associated b-galactosidase staining
(Figure 5C). This corresponds to an increase from 4.5%
senescence to 9.8% and 10.9% senescence, when comparing
untransduced cells to cells ectopically expressing MEOX1 and
MEOX2, respectively. Interestingly, expression of DNA binding
mutant MEOX2
Q235E in HUVECs did not result in increased
endothelial senescence (Figure 5C, 5D).
In addition to cell cycle arrest, p21
CIP1/WAF1 regulates
apoptosis. Changes in the percentage of apoptotic cells was
measured by terminal deoxynucleotidyl transferase mediated
dUTP nick end labeling (TUNEL). We did not observe increased
apoptosis when MEOX1 or MEOX2 was expressed in HUVECs
(Figure 5E). Furthermore, we did not observe any changes in
necrotic cell death, as assessed by live/dead (calcein AM/ethidium
homodimer-1) assay (data not shown). Thus, cell cycle inhibition
by the MEOX proteins does not lead to increased endothelial cell
death, under these conditions.
MEOX1 and MEOX2 activate transcription from a minimal
p21
CIP1/WAF1 promoter independent of its ability to bind
DNA
We first established the level of MEOX1 and MEOX2 induced
transcription of a luciferase reporter gene from a 2272 bp human
p21
WAF1/CIP1 promoter [33] in HEK293 cells. This 2272 bp
p21
CIP1/WAF1 promoter has been previously shown to be activated
by MEOX2 [25]. It contains several transcription factor binding
sites, including one p53 binding site, seven putative homeodomain
binding sites and six SP1 binding sites (Figure 6A). MEOX1 and
MEOX2 induced greater than two fold activation of the luciferase
reporter from the 2272 bp p21
CIP1/WAF1 promoter, when
compared to the empty vector control (Figure 6B). Interestingly,
the DNA binding deficient MEOX1
Q220E and MEOX2
Q235E
proteins were able to activate this luciferase reporter to a level
comparable to wild-type proteins (Figure 6B).
Progressive truncation of the 2272 bp p21
CIP1/WAF1 promoter
was performed in order to determine the minimal promoter that is
sufficient for MEOX2 induced transcription activation. It was
previously shown that MEOX2 activation of the p21
CIP1/WAF1
and a-tubulin was used as a loading control. The empty expression vector was used as a negative control (Ctrl). C) A representative western blot
demonstrating the subcellular localization of different MEOX proteins in HEK293 cells, 48 hours after transfection. a-tubulin was used as a
cytoplasmic (C) marker and lamin A/C was used as nuclear (N) marker. D) Representative fluorescent immunocytochemistry showing the localization
and level of expression of the MEOX proteins in HUVECs 48 hours after adenoviral transduction at a multiplicity of infection of 250. The N-terminally
tagged MEOX proteins were detected using an anti-FLAG antibody (green) and nuclei were stained with propidium iodide (red). Enhanced green
fluorescent protein (EGFP) was used as a control for adenoviral infection. Arrows indicate cytoplasmic staining and arrowheads indicate punctate
nuclear aggregates. Scale bar represents 20 mm.
doi:10.1371/journal.pone.0029099.g001
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equivalently activated an 849 bp p21
CIP1/WAF1 promoter, which
lacks the p53 binding site (Figure 6C). Furthermore, deletion of the
putative homeodomain binding sites did not affect MEOX2
induced transcription from the p21
CIP1/WAF1 promoter, as
demonstrated by the ability of MEOX2 to activate a 426 bp
p21
CIP1/WAF1 promoter (Figure 6C). Significant activation of the
luciferase reporter by MEOX1 and MEOX2 was still seen with
the smallest promoter tested, which contained only the most
proximal 232 bp of the p21
CIP1/WAF1 promoter (Figure 6D). This
Figure 2. MEOX1 and MEOX2 activate expression of p21
CIP1/WAF1 mRNA and protein in endothelial cells. A) Relative level of
endogenous p21
CIP1/WAF1 mRNA compared to EGFP transduced HUVECs. Total RNA was isolated from HUVECs 48 hours after adenoviral transduction
at a multiplicity of infection (MOI) of 250 and the amount of p21
CIP1/WAF1 mRNA was measured by quantitative real-time PCR. Beta-actin mRNA
expression was used for inter-sample normalisation. B) A representative western blot showing increased p21
CIP1/WAF1 protein in HUVECs expressing
ectopic MEOX2 (MX2) or DNA binding mutant MEOX2
Q235E (Q235E) but not MEOX1 (MX1). Total protein was isolated from HUVECs 48 hours after
adenoviral transduction at 250 MOI. C) Quantification of the relative amount of p21
CIP1/WAF1 protein compared to EGFP transduced HUVECs. The
intensity of the p21
CIP1/WAF1 band was normalized to the actin loading control. D) Activation of the 2272 bp p21
CIP1/WAF1 promoter driven luciferase
reporter gene by MEOX1 and MEOX2 in HEK293 and HUVECs. * Indicates a statistically significant change (p,0.05) when compared to the empty
vector or EGFP control. ¤ Indicates a statistically significant difference (p,0.05) between MEOX1 and MEOX2.
doi:10.1371/journal.pone.0029099.g002
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INK4a gene in HUVECs. A) Relative level of p16
INK4a mRNA in HUVECs. Total
RNA was isolated from HUVECs 72 hours after adenoviral transduction at a multiplicity of infection (MOI) of 250 and the amount of p16
INK4a mRNA
was measured by quantitative real-time PCR and compared to EGFP transduced HUVECs. Beta-actin mRNA expression was used for inter-sample
normalisation. MEOX1 is a more potent activator of p16
INK4a than MEOX2. B) A representative western blot showing increased p16
INK4a protein in
HUVECs expressing ectopic MEOX1 (MX1), MEOX2 (MX2), but not DNA binding mutant MEOX2
Q235E (Q235E). Total protein was isolated from HUVECs
72 hours after adenoviral transduction at 250 MOI. C) Quantification of the relative amount of p16
INK4a protein compared to EGFP transduced
HUVECs. The intensity of the p16
INK4a band was normalized to the tubulin loading control. D) Schematic diagram of the human p16
INK4a promoter
luciferase construct used in this paper. The base pair positions are indicated relative to the translational start site. E) Activation of the luciferase
reporter gene from the 564 bp p16
INK4a promoter by wild type MEOX1 and MEOX2 but not by the DNA binding domain mutant versions of MEOX2
(MEOX2
Q235E) or MEOX1 (MEOX1
Q220E). Luciferase assays were performed in HUVECs. * Indicates a statistically significant change (p,0.05) when
compared to the empty vector or EGFP control. ¤ Indicates a statistically significant difference (p,0.05) between MEOX1 and MEOX2.
doi:10.1371/journal.pone.0029099.g003
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main binding sites. MEOX1
Q220E and MEOX2
Q235E were also
both able to activate transcription from the 232 bp p21
CIP1/WAF1
promoter (Figure 6D), suggesting that MEOX1 and MEOX2 do
not need to bind DNA in order to induce p21
CIP1/WAF1
transcription. Notably, MEOX2
Q235E was able to activate
endogenous p21
CIP1/WAF1 expression at the mRNA and protein
levels to equivalent degrees as observed for wild-type MEOX2
(Figure 2A, 2B, 2C). This result further demonstrated that
activation of the p21
CIP1/WAF1 gene by MEOX2 is DNA-binding
independent.
In order to verify that MEOX1
Q220E and MEOX2
Q235E are
unable to bind to DNA, we performed electrophoretic mobility
shift assays (EMSAs) using a sequence from the p21
CIP1/WAF1
promoter previously shown to contain a MEOX2 binding site [15]
(Figure S4; Figure S5, panel D). This sequence is not contained
within the 2272 bp p21
CIP1/WAF1 luciferase promoter; it is located
approximately 9.5 kb upstream of the p21
CIP1/WAF1 transcription
Figure 4. MEOX1 and MEOX2 bind to the proximal homeodomain binding site in the p16
INK4a promoter. Electrophoretic mobility shift
assays were used to assess the ability of the MEOX proteins to bind to the homeodomain binding sites within the p16
INK4a luciferase promoter. The
DNA probes each contained one homeodomain binding site and correspond to 2833 to 2862 bp (Distal) and 2538 to 2567 bp (Proximal) upstream
of the p16
INK4a translation start site. A) Neither recombinant GST-tagged MEOX1 (MX1) nor MEOX2 (MX2) bound to the Distal probe (left). Both
MEOX1 and MEOX2 clearly bound to the Proximal probe (right, arrow), while MEOX2
Q235E (Q235E) and GST did not. B) Nuclear extracts from HUVECs
expressing N-terminally FLAG tagged MEOX1 or MEOX2 were not able to shift the Distal probe since no unique complexes were seen upon their
expression (left). Incubation of nuclear extracts from HUVECs infected with MEOX1 or MEOX2 with the Proximal probe resulted in the formation of
distinct complexes (arrows) (right), indicating that both MEOX proteins can bind to this sequence. Addition of FLAG antibody caused this protein-
probe complex to super-shift (arrowhead), confirming that the observed shift is a MEOX protein-probe complex. Incubation of nuclear extracts from
HUVECs expressing MEOX2
Q235E were unable to cause a specific shift of the DNA probes and a super-shift was not observed in the presence of FLAG
antibody. Nuclear extracts from HUVECs expressing enhanced green fluorescent protein (EGFP) were used as a negative control.
doi:10.1371/journal.pone.0029099.g004
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proteins as well as nuclear extracts from HUVECs and HEK293
cells expressing FLAG tagged MEOX proteins (Figure S4, panels
A,C; Figure S5, panel D), both MEOX1 and MEOX2 were able
to bind this probe. Unlike wild-type MEOX proteins, no shift was
observed with MEOX1
Q220E (Figure S5, panel D) or
MEOX2
Q235E (Figure S4, panels A,C; Figure S5, panel D),
indicating that these proteins are indeed unable to bind to this
probe. GST alone (Figure S4, panels A,B), nuclear extracts
from EGFP expressing HUVECs (Figure S4, panels C,D) and
nuclear extracts from HEK293 cells transfected with empty vector
(Figure S5, panel D) were used as negative controls for DNA
binding.
Role of SP1 in mediating effects of MEOX1 and MEOX2
on p21
CIP1/WAF1 transcription
Our data identifies the MEOX responsive region of the
p21
WAF1/CIP1 promoter as residing within the most proximal
232 bp, through which it activates transcription independent of
DNA binding. This region does not contain homeodomain
binding sites but does contain several SP1 binding sites. To
interrogate the role of SP1 in mediating MEOX activation of the
p21
CIP1/WAF1 promoter, we co-transfected MEOX1 or MEOX2
with and without SP1. We determined that either MEOX1 or
MEOX2, together with SP1, synergistically activated transcription
from the 232 bp p21
CIP1/WAF1 promoter (Figure 7A). To inhibit
SP1 binding, we treated cells that were transfected with the 232
p21
CIP1/WAF1 promoter and MEOX expression plasmids with
mithramycin A. Mithramycin A binds GC-rich regions of DNA
and thereby inhibits SP1 interaction with its binding sites [37,38].
This treatment blocked the MEOX mediated activation of the
232 bp p21
CIP1/WAF1 promoter (Figure 7B). Next, we studied the
ability of MEOX2 to activate transcription from a 103 bp
p21
CIP1/WAF1 promoter with wild-type or mutated SP1 binding
sites (Figure 7C) [34,35]. Only mutation of the most upstream SP1
binding site abolished the ability of MEOX2 to activate
transcription from this promoter (Figure 7D).
Discussion
Our results demonstrate for the first time that MEOX1
regulates the MEOX2 target genes p21
CIP1/WAF1 and p16
INK4a.
We observed that increased expression of the MEOX homeodo-
main transcription factors leads to both cell cycle arrest and
endothelial cell senescence. Furthermore we showed that the
mechanism of transcriptional activation of these cyclin dependent
kinase inhibitor genes by MEOX1 and MEOX2 is distinct; the
MEOX proteins activate p16
INK4a in a DNA-binding dependent
manner, whereas they induces p21
CIP1/WAF1 in a DNA binding
independent manner, which requires SP1.
Knockout of both MEOX1 and MEOX2 in mice produces a
phenotype that is more severe than what the additive phenotypes
of the single MEOX gene knockout mice would be [30], indicating
that these proteins have partially redundant functions. Our data
provides evidence that the MEOX transcription factors regulate
the expression of similar sets of target genes. In support of this
notion, the amino acid composition of the MEOX1 and MEOX2
homeodomains (HD) is nearly identical (Figure 1A). Indeed,
MEOX2 has been shown by EMSA to bind to the MEOX1
binding site within the NKX3-2/BapX1 promoter [31]. Addi-
tionally, we show that MEOX1 and MEOX2 are able to bind
DNA probes which contain homeodomain binding sites from the
p21
CIP1/WAF1 and p16
INK4a promoters (Figure 4, Figure S4).
Aside from the homeodomain, there is only limited sequence
conservation between MEOX1 and MEOX2. Differences in
MEOX1 versus MEOX2 activation of common target genes are
likely to be due to: i) the presence of unique transactivation motifs
within these proteins, or ii) the ability of these proteins to interact
with distinct transcriptional co-factors via protein-protein interac-
tion domains. The HQ domain of MEOX2 was shown to be
important for the ability of MEOX2 to activate transcription from a
2.4 Kb p21
CIP1/WAF1 promoter, as deletion of this domain
dramatically decreased MEOX2 induced reporter gene expression
[15]. Similar polyhistidine/polyglutamine rich motifs are found in
other human proteins [43,44], such as the homeodomain
transcription factor HOXA1, a known transcriptional activator
[45]. Interestingly, MEOX1 does not contain an HQ rich domain,
but is still able to activate transcription of p21
CIP1/WAF1 and
p16
INK4a. Surprisingly, deletion of the MEOX2 HQ rich domain
did not alter protein localization, expression or function (Figure S5).
Unlike the HQ domain, there are currently no known functions
for the MID domain. Outside of the homeodomain, the MID
domain is the next most highly conserved domain between
MEOX1 and MEOX2 (Figure 1A). Furthermore, the MID
region, along with the homeodomain, was shown to be important
in the regulation of the p16
INK4a gene [16]. In addition, this region
of MEOX2 is sufficient for binding to vascular endothelial zinc-
finger 1 (VEZF1) protein in yeast-two-hybrid assays (unpublished
observation). These results suggest that the MID domain of the
MEOX proteins may play a role in mediating protein-protein
interactions with other transcription factors.
MEOX1 and MEOX2 differ slightly in subcellular localization;
both MEOX1 and MEOX2 were detected throughout the nucleus,
however MEOX1 was also detected in the cytosol (Figure 1C, 1D).
Although the reason for this difference in localization is not known,
we speculate that unique protein binding partners may explain the
cytosolic localization of MEOX1. Despite the difference in cytosolic
protein, both MEOX1 and MEOX2 are transcriptionally active
within the nucleus, as shown by their ability to increase the
expression of the p21
CIP1/WAF1 and p16
INK4a genes.
Figure 5. Increased MEOX1 or MEOX2 expression leads to increased endothelial cell senescence. A) Representative flow cytometry
showing the density of BrdU
+ endothelial cells (upper left and right quadrants). HUVECs were transduced with N-terminal FLAG tagged MEOX1 and
MEOX2 adenoviral constructs at a multiplicity of infection (MOI) of 100; 48 hours later, cells were labeled with BrdU for one hour prior to fixation. DNA
was stained with 7-aminoactinomycin D (7-AAD). B) Quantification of the flow cytometry data. Expression of MEOX1, MEOX2 and MEOX2
Q235E mutant
decreased cellular proliferation comparable to p53 (positive control) as assessed by BrdU incorporation into cycling cells. C) Representative images
showing SA-b-gal
+ cells (blue). Nuclei were stained with hematoxylin (brown). D) Quantification of SA-b-gal
+ cells shows that both MEOX1 and
MEOX2 expression increased the number of senescent HUVECs. In contrast, MEOX2
Q235E expression did not alter the level of endothelial cell
senescence. HUVECs were transduced with N-terminal FLAG tagged MEOX1 and MEOX2 adenoviral constructs at a MOI of 250; 48 hours later cells
were fixed and stained. D) MEOX proteins do not induced endothelial cell apoptosis. HUVECs were transduced with FLAG tagged MEOX1, MEOX2 and
MEOX2
Q235E adenoviral constructs at a MOI of 250; 48 hours later cells were fixed and stained. Staurosporine was used as a positive control for
apoptosis induction. * Indicates a statistically significant change (p,0.05) when compared to the EGFP control. ¤ Indicates a statistically significant
difference (p,0.05) between MEOX1 and MEOX2.
doi:10.1371/journal.pone.0029099.g005
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INK4a is a known target of MEOX2 regulation, to
our surprise MEOX1 was a much stronger activator of p16
INK4a
expression in HUVECs (Figure 3A, 3B, 3C). In contrast, MEOX1
was a weaker inducer of p21
CIP1/WAF1 protein expression, when
compared to MEOX2 (Figure 2C). We observed that MEOX1 had
the greatest effect on inhibiting cellular proliferation (Figure 5A, 5B),
conceivably due to its strong induction of p16
INK4a expression.
However, despite the difference in p21
CIP1/WAF1 and p16
INKa
expression, MEOX1 and MEOX2, were similarly able to induce
senescence (Figure 5B, 5C), further supporting the hypothesis that
Figure 6. MEOX2 activates transcription from a minimal p21
CIP1/WAF1 promoter independent of its ability to bind DNA. A) Schematic
diagram of the human p21
CIP1/WAF1 promoter luciferase constructs used in this paper. The 59 termini are indicated relative to the transcriptional start
site (arrow). Relevant transcription factor binding sites (p53, homeodomain, SP1 and TATA) are also shown. B) Activation of the luciferase reporter
gene from the 2272 bp p21
CIP1/WAF1 promoter by wild type MEOX1, MEOX2 and their respective DNA binding mutant versions MEOX1
Q220E and
MEOX2
Q235E. C) Comparison of MEOX2 activation from the 2272 bp, 849 bp, 505 bp and 426 bp p21
CIP1/WAF1 promoters. The fold activation by
MEOX2 compared to the empty vector control is indicated for each promoter. D) Activation of the luciferase reporter gene from the minimal 232 bp
p21
CIP1/WAF1 promoter by wild type MEOX1, MEOX2 and their respective DNA binding mutant versions MEOX1
Q220E and MEOX2
Q235E. B-D). All
luciferase assays were performed in HEK293 cells. * Indicates a statistically significant change (p,0.05), when compared to the empty vector control.
doi:10.1371/journal.pone.0029099.g006
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CIP1/WAF1 and p16
INK4a
are required for the induction of the cellular senescence program in
HUVECs. To our knowledge, the MEOX proteins are the second
instance of homeodomain transcription factors capable of inducing
senescence. Ectopic expression of VentX, a transactivator of
p16
INK4a, has recently been shown to cause senescence in cancer
cells [46].Corresponding to ourresults,these authors showthatboth
p21
CIP1/WAF1 and p16
INK4a are involved in permanent cell cycle
arrest.
In contrast to p21
CIP1/WAF1, we show that MEOX1 and
MEOX2 require the ability to bind to DNA in order to activate
transcription of the p16
INK4a gene. Unlike wild-type MEOX1 and
MEOX2, MEOX1
Q220E and MEOX2
Q235E were unable to
induce p16
INK4a expression in HUVECs (Figure 3B, 3C, 3E).
Furthermore, ectopic MEOX2
Q235E expression decreased the
proportion of S phase cells to the same extent as wild-type
MEOX2 (Figure 5B), but did not lead to increased senescence in
HUVECs (Figure 5D). This finding suggests that p21
CIP1/WAF1 is
Figure 7. MEOX1 and MEOX2 activation of the p21
CIP1/WAF1 promoter is dependent on SP1 function. A) Co-transfection of SP1 enhanced
the activation of the 232 bp p21
CIP1/WAF1 promoter by both MEOX1 and MEOX2. B) Treatment of cells with mithramyin A but not vehicle (methanol)
for 24 hours blocked MEOX1 and MEOX2 mediated activation of the reporter gene from the 232 bp p21
CIP1/WAF1 promoter. C) Schematic diagram of
the human 103 bp p21
CIP1/WAF1 promoter luciferase constructs used in this paper. D) Activation of the luciferase reporter gene from the 103 bp
p21
CIP1/WAF1 promoter by MEOX2 was abolished through mutation of the most upstream SP1 site. WT = Wild-type promoter, MT = mutant
promoters. * Indicates a statistically significant change (p,0.05), when compared to the empty vector control. N Indicates a statistically significant
difference (p,0.05) between MEOX+Control and MEOX+SP1. # Indicates a statistically significant difference (p,0.05) between vehicle and
mithramycin A treatment.
doi:10.1371/journal.pone.0029099.g007
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expression; however both p21
CIP1/WAF1 and p16
INK4a are
required for the induction of the cellular senescence program in
HUVECs. Alternatively, MEOX2 may activate other genes
required for senescence in a DNA binding dependent manner.
Canonically, control of target gene transcription by homeodo-
main proteins is achieved through direct binding of DNA via the
homeodomain.However,the homeodomainhasalsobeenshownto
act as a critical protein-protein interaction domain in several
homeodomain proteins, including MEOX2 [47,48], thereby
permitting homeodomain transcription factors to modify target
gene transcription without binding DNA directly. For our study, we
created DNA binding deficient versions of the MEOX1 and
MEOX2 proteins (MEOX1
Q220E and MEOX2
Q235E) by mutating
the amino acid at position 50 of the homeodomain from a positively
charged glutamine to a negatively charged glutamate (Figure 1A).
Mutation of this highly conserved residue within the homeodomain
hasbeen usedpreviouslytoeffectivelyabolish DNAbindingofother
homeodomain transcription factors [40,41]. MEOX1
Q220E and
MEOX2
Q235E are full-length proteins and are localized to the
nucleus like wild-type MEOX proteins (Figure 1C, 1D). Therefore,
mutation of the MEOX homeodomain abolished DNA binding
(Figure 4A, 4B; Figure S4, panels A,C; Figure S5, panel D), but is
unlikely to affect the ability of MEOX proteins to form protein-
protein interactions. In contrast, the homeodomain deleted ver-
sion of MEOX2 (MEOX2
K195_K245del) was localized to punctate
nuclear aggregates and was consistently detected in the cyto-
plasm (Figure 1C, 1D). The cytoplasmic localization of the
MEOX2
K195_K245del protein occurred despite the predicted nuclear
localization signal being left intact. The punctate nuclear aggregates
of homeodomain deleted MEOX2 have been shown to co-localize
with splicing factor SC35, a component of the nuclear speckles [44].
Thus, the deletion of the MEOX2 homeodomain resulted in a loss
of DNA binding but also likely affected protein function due to
altered localization and disrupted protein-protein interactions.
MEOX2 activation of the p21
CIP1/WAF1 gene was reported to
be dependent upon DNA binding, as a homeodomain deleted
version of MEOX2 could not activate transcription from a 2.4 Kb
p21
CIP1/WAF1 promoter [15,25]. However, we postulate that the
homeodomain deleted MEOX2 is unable to activate transcription
from the p21 promoter because of its improper subcellular
localization which may make it unable to associate with either the
p21 gene or requisite transcriptional co-factors.
In this study we show that MEOX2
Q235E was as effective as
wild-type MEOX2 at inducing p21
CIP1/WAF1 expression in
primary endothelial cells (Figure 2A, 2B, 2C). Furthermore,
removal of all the putative homeodomain binding sites from the
p21
CIP1/WAF1 promoter did not affect the ability of MEOX1 or
MEOX2 to activate transcription from the p21
CIP1/WAF1
promoter (Figure 6D). Combined, this led us to conclude that
MEOX activation of the p21
CIP1/WAF1 gene is DNA-binding
independent, and likely occurs through interaction with other
transcription co-factors. MEOX1, MEOX1
Q220E, MEOX2 and
MEOX2
Q235E were all able to activate transcription from the
232 bp p21
CIP1/WAF1 luciferase promoter which contains six SP1
binding sites (Figure 6A, 6D). Thus, we hypothesized that the
MEOX proteins may interact with SP1 or co-operate with other
transcription factors which activate the p21
CIP1/WAF1 gene from
this minimal region [49–58]. Indeed, increasing SP1 expression
enhanced MEOX mediated activation, whereas mithramycin A
blunted MEOX mediated activation, of the 232 bp p21
CIP1/WAF1
luciferase promoter (Figure 7A, 7B). Furthermore, we show that
mutation of a single SP1 site in a 103 bp p21
CIP1/WAF1 luciferase
promoter abolished MEOX2 induced activation (Figure 7D).
Age is a major risk factor for cardiovascular diseases, such as
atherosclerosis. As blood vessels age, they accumulate increasing
numbers of senescent cells, leading to endothelial dysfunction and
ultimately vascular disease [6,7]. Indeed, human atherosclerotic
tissue has been shown to contain a higher proportion of senescent
cells [8–10]. Furthermore, children affected by Hutchison-Gilford
Progeria Syndrome, a disease of premature aging, often die from
accelerated atherosclerosis [7,59]. Microarray analysis has shown
that MEOX2 expression is increased 10-fold in cells from
Hutchison-Gilford Progeria Syndrome patients [59]. Thus,
MEOX proteins may play a role in endothelial aging and
atherosclerosis, by inhibiting cell cycle progression and inducing
endothelial cell senescence.
In summary, we show that MEOX1 can activate the known
MEOX2 target genes p21
CIP1/WAF1 and p16
INK4a in primary
endothelial cells and induce endothelial senescence. In addition,
our findings demonstrate that MEOX2 activates transcription of
p21
CIP1/WAF1 independent of DNA binding. Thus, future studies
to identify novel MEOX1 and MEOX2 target genes will aim to
determine whether activation occurs via DNA binding dependent
or independent mechanisms. In addition, for DNA binding
independent target genes, such as p21
CIP1/WAF1, experiments will
be done to identify transcription co-factors of the MEOX proteins.
Together, these findings may provide further insight into how the
MEOX proteins induce senescence and shed light on the role of
the MEOX proteins in the pathogenesis of atherosclerosis.
Supporting Information
Figure S1 Ectopic MEOX proteins are expressed at
similar levels. N-terminally tagged MEOX proteins were
detected using an anti-FLAG antibody and a-tubulin was used
as a loading control. A) A representative western blot displaying
the relative level of MEOX protein expression in HEK293 cells
24 hours after transfection. Each lane represents an independent
transfection. B) Representative western blot displaying the relative
level of MEOX protein expression in HUVECs 48 hours after
adenoviral transduction at an MOI of 250. Each lane represents
an independent transduction.
(TIF)
Figure S2 The position or inclusion of the FLAG epitope
does not affect MEOX2 function. Luciferase assay demon-
strating the ability of N-terminal, C-terminal and non-FLAG
tagged MEOX2 proteins to activate a 2272 bp p21
CIP1/WAF1
promoter. * Indicates a statistically significant change (p,0.05)
when compared to the empty vector controls. n.s. denotes no
statistically significant difference (p,0.05) in promoter activation is
observed between the various MEOX2 proteins.
(TIF)
Figure S3 MEOX proteins bind to the proximal homeo-
domain binding site in the p16
INK4a promoter. A)
Overexposure of the p16
INK4a EMSA shown in Figure 6B, left.
Incubation of nuclear extracts from HUVECs infected with
MEOX1 or MEOX2 with the Proximal probe resulted in the
formation of distinct complexes (arrowhead) (left), indicating that
both MEOX proteins can bind to this sequence. Addition of
FLAG antibody caused this protein-probe complex to super-shift
(arrowhead) (right), confirming that the observed shift is a MEOX
protein-probe complex. Incubation of nuclear extracts from
HUVECs expressing MEOX2
Q235E were unable to cause a
specific shift of the DNA probes and a super-shift was not observed
in the presence of FLAG antibody. Nuclear extracts from
HUVECs expressing enhanced green fluorescent protein (EGFP)
MEOX1/2 Induce p21, p16 and Endothelial Senescence
PLoS ONE | www.plosone.org 14 December 2011 | Volume 6 | Issue 12 | e29099were used as a negative control. B) Binding of MEOX1 (right) and
MEOX2 (left) to the Proximal probe could be competed with
excess wild type (WT), but not mutant (MT) cold probe, in which
the homeodomain binding site was abolished.
(TIF)
Figure S4 MEOX1 and MEOX2, but not MEOX2
Q235E,
bind to a region of the p21
CIP1/WAF1 promoter. Electro-
phoretic mobility shift assays (EMSAs) were used to assess the
DNA binding capabilities of the various MEOX proteins. The
DNA probe contained two MEOX2 binding sites originating from
the sequence 29519 bp to 29489 bpupstream of the p21
CIP1/WAF1
transcription start site. A) Recombinant GST-tagged MEOX1
(MX1)andMEOX2(MX2)boundtotheprobe(arrow)whereasthe
DNA binding domain mutant version of MEOX2 (Q235E) and
GST alone did not. B) Binding of MEOX2 to the DNA probe could
be competed withexcesswild type (WT), butnot with excessmutant
(MT) cold probe, in which the homeodomain binding sites were
mutated. C) Nuclear extracts from HUVECs expressing N-
terminally FLAG tagged MEOX1 and MEOX2 resulted in distinct
shifted complexes (arrows), that were not seen with the EGFP or
MEOX2
Q235E nuclear extracts. Addition of FLAG antibody to
nuclear extracts from MEOX1 and MEOX2 infected cells, but not
EGFP or MEOX2
Q235E infected cells, resulted in the formation of a
super-shift complex (arrowhead). D) Binding of the DNA probe by
MEOX2 in endothelial cell nuclear extracts was competed with
excess wild type (WT), but not mutant (MT) cold probe. Addition of
FLAG antibody, but not non-immune IgG, caused the formation of
a super-shift complex (arrowhead).
(TIF)
Figure S5 Deletion of the HQ rich domain of MEOX2
does not alter protein expression, localization or
function. A) Schematic representation of the MEOX2
H68_Q85del
protein compared to wild-type MEOX1 and MEOX2. B) A
representative western blot demonstrating the subcellular locali-
zation of MEOX2
H68_Q85del protein compared to wild-type
MEOX2 in HEK293 cells, 48 hours after transfection. a-tubulin
was used as a cytoplasmic (C) marker and lamin A/C was used as
nuclear (N) marker. C) Representative fluorescent immunocyto-
chemistry showing the localization and level of expression of the
MEOX proteins in HEK293 cells 24 hours after transfection. The
N-terminally tagged MEOX proteins were detected using an anti-
FLAG antibody (green) and nuclei were stained with DAPI (blue).
Empty vector was used as a negative control. D) Incubation of
nuclear extracts from HEK293 cells transfected with MEOX1,
MEOX2 or MEOX2
H68_Q85del with the p21 probe resulted in the
formation of distinct complexes (arrows). Homeodomain mutated
MEOX1
Q220E and MEOX2
Q235E were unable to cause a specific
shift of the DNA probe. E) MEOX2
H68_Q85del activation of the
luciferase reporter gene from the 232 bp p21
CIP1/WAF1 promoter
is comparable to wild type MEOX2.
(TIF)
Table S1 List of PCR primers used to create MEOX1
and MEOX2 fusion proteins.
(DOC)
Table S2 List of PCR primers used to create the
p21
CIP1/WAF1 promoter luciferase constructs.
(DOC)
Table S3 List of PCR primers used for qRT-PCR.
(DOC)
Table S4 List of EMSA probes.
(DOC)
Methods S1 Supplementary methods.
(DOC)
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